Within weeks of joining forces with the University of Oxford to develop a candidate vaccine for COVID-19, AstraZeneca Plc has secured manufacturing capacity to produce two billion doses of the prospective treatment as well as financial support of more than $1 billion from an agency of the US government. The company has harnessed resources quickly, even though vaccines are not one of its core therapy areas.
